Characterizing immune profiles in hepatocellular carcinoma patients benefiting from pembrolizumab and lenvatinib using machine learning
This study recognized distinct ICPs between uHCC patients with and without tumor response to PL therapy and identified key contributing immune subpopulations. These findings provide a foundation for developing predictive tools for clinical outcomes before initiating combination immunotherapy.
Authors
- Jan-Mou Lee
- Pei-Chang Lee
- Yee Chao (ORCID: https://orcid.org/0000-0001-5578-340X)
- Hsien-Chen Mon
- Shian‐Ren Lin (ORCID: https://orcid.org/0000-0002-4160-2361)
- I‐Cheng Lee (ORCID: https://orcid.org/0000-0002-9316-4682)
- Cheng-Yun Lee
- Yi‐Hsiang Huang (ORCID: https://orcid.org/0000-0001-5241-5425)
- Ya‐Wen Hung
- Chieh-Ju Lee
- Peixun Li (ORCID: https://orcid.org/0000-0002-7749-1472)
- Yuhua Chen (ORCID: https://orcid.org/0000-0002-0540-1984)
- J.K. Chan
- Chi-Jung Wu
- Ming-Chih Hou
- Chen‐Ta Chi
Institutions
- National Yang Ming Chiao Tung University (TW)
- Taipei Veterans General Hospital (TW)
- H.B. Fuller (United States) (US)
- Tao Yuan General Hospital (TW)
- Taipei City Hospital (TW)
- Taipei Hospital (TW)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-10-24
- DOI
- https://doi.org/10.1186/s12885-025-14945-9
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Shanghai Educational Development Foundation
- Taipei Veterans General Hospital
- National Science and Technology Council